Cargando…

Is left ventricular hypertrophy a friend or foe of patients with aortic stenosis?

Left ventricular hypertrophy (LVH) is traditionally considered a physiological compensatory response to LV pressure overload, such as hypertension and aortic stenosis (AS), in an effort to maintain LV systolic function in the face of an increased afterload. According to the Laplace law, LV wall thic...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Cecilia, Zerebiec, Katherine, Rożanowska, Agnieszka, Czestkowska, Ewa, Długosz, Dorota, Chyrchel, Bernadeta, Surdacki, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309834/
https://www.ncbi.nlm.nih.gov/pubmed/30603022
http://dx.doi.org/10.5114/aic.2018.78734
_version_ 1783383387440939008
author Davies, Cecilia
Zerebiec, Katherine
Rożanowska, Agnieszka
Czestkowska, Ewa
Długosz, Dorota
Chyrchel, Bernadeta
Surdacki, Andrzej
author_facet Davies, Cecilia
Zerebiec, Katherine
Rożanowska, Agnieszka
Czestkowska, Ewa
Długosz, Dorota
Chyrchel, Bernadeta
Surdacki, Andrzej
author_sort Davies, Cecilia
collection PubMed
description Left ventricular hypertrophy (LVH) is traditionally considered a physiological compensatory response to LV pressure overload, such as hypertension and aortic stenosis (AS), in an effort to maintain LV systolic function in the face of an increased afterload. According to the Laplace law, LV wall thickening lowers LV wall stress, which in turn would be helpful to preserve LV systolic performance. However, numerous studies have challenged the notion of LVH as a putative beneficial adaptive mechanism. In fact, the magnitude of LVH is associated with higher cardiovascular morbidity and mortality, especially when LVH is disproportionate to LV afterload. We have briefly reviewed: first, the importance of non-valvular factors, beyond AS severity, for total LV afterload and symptomatic status in AS patients; second, associations of excessive LVH with LV dysfunction and adverse outcome in AS; third, prognostic relevance of the presence or absence of pre-operative LVH in patients referred for aortic valve surgery; fourth, time course, determinants and prognostic implications of LVH regression and LV function recovery after surgical valve replacement and transcatheter aortic valve implantation (TAVI) with a focus on TAVI-specific effects; fifth, the potential of medical therapy to modulate LVH before and after surgical or interventional treatment for severe AS, a condition perceived as a relative contraindication to renin-angiotensin system blockade.
format Online
Article
Text
id pubmed-6309834
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-63098342019-01-02 Is left ventricular hypertrophy a friend or foe of patients with aortic stenosis? Davies, Cecilia Zerebiec, Katherine Rożanowska, Agnieszka Czestkowska, Ewa Długosz, Dorota Chyrchel, Bernadeta Surdacki, Andrzej Postepy Kardiol Interwencyjnej Review Paper Left ventricular hypertrophy (LVH) is traditionally considered a physiological compensatory response to LV pressure overload, such as hypertension and aortic stenosis (AS), in an effort to maintain LV systolic function in the face of an increased afterload. According to the Laplace law, LV wall thickening lowers LV wall stress, which in turn would be helpful to preserve LV systolic performance. However, numerous studies have challenged the notion of LVH as a putative beneficial adaptive mechanism. In fact, the magnitude of LVH is associated with higher cardiovascular morbidity and mortality, especially when LVH is disproportionate to LV afterload. We have briefly reviewed: first, the importance of non-valvular factors, beyond AS severity, for total LV afterload and symptomatic status in AS patients; second, associations of excessive LVH with LV dysfunction and adverse outcome in AS; third, prognostic relevance of the presence or absence of pre-operative LVH in patients referred for aortic valve surgery; fourth, time course, determinants and prognostic implications of LVH regression and LV function recovery after surgical valve replacement and transcatheter aortic valve implantation (TAVI) with a focus on TAVI-specific effects; fifth, the potential of medical therapy to modulate LVH before and after surgical or interventional treatment for severe AS, a condition perceived as a relative contraindication to renin-angiotensin system blockade. Termedia Publishing House 2018-10-03 2018 /pmc/articles/PMC6309834/ /pubmed/30603022 http://dx.doi.org/10.5114/aic.2018.78734 Text en Copyright: © 2018 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Review Paper
Davies, Cecilia
Zerebiec, Katherine
Rożanowska, Agnieszka
Czestkowska, Ewa
Długosz, Dorota
Chyrchel, Bernadeta
Surdacki, Andrzej
Is left ventricular hypertrophy a friend or foe of patients with aortic stenosis?
title Is left ventricular hypertrophy a friend or foe of patients with aortic stenosis?
title_full Is left ventricular hypertrophy a friend or foe of patients with aortic stenosis?
title_fullStr Is left ventricular hypertrophy a friend or foe of patients with aortic stenosis?
title_full_unstemmed Is left ventricular hypertrophy a friend or foe of patients with aortic stenosis?
title_short Is left ventricular hypertrophy a friend or foe of patients with aortic stenosis?
title_sort is left ventricular hypertrophy a friend or foe of patients with aortic stenosis?
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309834/
https://www.ncbi.nlm.nih.gov/pubmed/30603022
http://dx.doi.org/10.5114/aic.2018.78734
work_keys_str_mv AT daviescecilia isleftventricularhypertrophyafriendorfoeofpatientswithaorticstenosis
AT zerebieckatherine isleftventricularhypertrophyafriendorfoeofpatientswithaorticstenosis
AT rozanowskaagnieszka isleftventricularhypertrophyafriendorfoeofpatientswithaorticstenosis
AT czestkowskaewa isleftventricularhypertrophyafriendorfoeofpatientswithaorticstenosis
AT długoszdorota isleftventricularhypertrophyafriendorfoeofpatientswithaorticstenosis
AT chyrchelbernadeta isleftventricularhypertrophyafriendorfoeofpatientswithaorticstenosis
AT surdackiandrzej isleftventricularhypertrophyafriendorfoeofpatientswithaorticstenosis